CY1110913T1 - Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα - Google Patents
Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικαInfo
- Publication number
- CY1110913T1 CY1110913T1 CY20101101028T CY101101028T CY1110913T1 CY 1110913 T1 CY1110913 T1 CY 1110913T1 CY 20101101028 T CY20101101028 T CY 20101101028T CY 101101028 T CY101101028 T CY 101101028T CY 1110913 T1 CY1110913 T1 CY 1110913T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyrrolidin
- oxadiasol
- ylo
- anticipates
- production
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- HYSNXVPAKDTRDH-UHFFFAOYSA-N 2-pyrrolidin-2-yl-1,3,4-oxadiazole Chemical class C1CCNC1C1=NN=CO1 HYSNXVPAKDTRDH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10240818A DE10240818A1 (de) | 2002-08-30 | 2002-08-30 | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| EP03794933A EP1532141B1 (de) | 2002-08-30 | 2003-08-25 | 2-pyrrolidin-2-yl-[1,3,4] -oxadiazol-derivate und ihre verwendung als antidepressiva |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110913T1 true CY1110913T1 (el) | 2015-06-10 |
Family
ID=31983895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101101028T CY1110913T1 (el) | 2002-08-30 | 2010-11-17 | Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7105538B2 (enExample) |
| EP (1) | EP1532141B1 (enExample) |
| JP (1) | JP2006506348A (enExample) |
| CN (1) | CN100390168C (enExample) |
| AR (1) | AR041093A1 (enExample) |
| AT (1) | ATE484503T1 (enExample) |
| CA (1) | CA2497078A1 (enExample) |
| CY (1) | CY1110913T1 (enExample) |
| DE (2) | DE10240818A1 (enExample) |
| DK (1) | DK1532141T3 (enExample) |
| ES (1) | ES2351119T3 (enExample) |
| MX (1) | MXPA05002298A (enExample) |
| PE (1) | PE20040983A1 (enExample) |
| PL (1) | PL375627A1 (enExample) |
| PT (1) | PT1532141E (enExample) |
| RU (1) | RU2324694C2 (enExample) |
| SI (1) | SI1532141T1 (enExample) |
| WO (1) | WO2004024725A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2291080E (pt) | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| RU2417995C1 (ru) * | 2009-09-21 | 2011-05-10 | Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") | Способ получения 3-(2-замещенных-1,3-оксазол-4-ил)пиридин-2(1н)-онов |
| CN103420998A (zh) * | 2012-05-16 | 2013-12-04 | 苏州爱斯鹏药物研发有限责任公司 | 一种新型噁二唑衍生物的合成方法 |
| DK2855453T3 (en) | 2012-06-04 | 2017-02-06 | Actelion Pharmaceuticals Ltd | Benzimidazol-proline derivatives |
| US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
| BR112015007516A2 (pt) * | 2012-10-10 | 2017-07-04 | Actelion Pharmaceuticals Ltd | antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona |
| CN105051040A (zh) * | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| CN103333165B (zh) * | 2013-07-01 | 2016-02-24 | 河南理工大学 | 2-苯基-5-(3,4-二甲基)吡咯基-1,3,4-噁二唑及制备方法 |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| CN111978311B (zh) * | 2019-05-21 | 2024-05-31 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215949B1 (enExample) * | 1973-02-01 | 1976-07-02 | Delalande Sa | |
| US4784998A (en) * | 1987-04-06 | 1988-11-15 | Bristol-Myers Company | 1,3,4-oxadiazole pyschotropic compounds |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| US5965537A (en) * | 1997-03-10 | 1999-10-12 | Basf Aktiengesellschaft | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus |
| CN1382140A (zh) * | 1999-07-09 | 2002-11-27 | 奥索-麦克尼尔药品公司 | 具有神经营养活性的吡咯烷和哌啶、以及含有它们的相关组合物 |
| JP2001247569A (ja) * | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| US6589978B2 (en) * | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
-
2002
- 2002-08-30 DE DE10240818A patent/DE10240818A1/de not_active Withdrawn
-
2003
- 2003-08-25 RU RU2005109164/04A patent/RU2324694C2/ru not_active IP Right Cessation
- 2003-08-25 EP EP03794933A patent/EP1532141B1/de not_active Expired - Lifetime
- 2003-08-25 DK DK03794933.6T patent/DK1532141T3/da active
- 2003-08-25 WO PCT/EP2003/009390 patent/WO2004024725A1/de not_active Ceased
- 2003-08-25 CN CNB038201976A patent/CN100390168C/zh not_active Expired - Fee Related
- 2003-08-25 PT PT03794933T patent/PT1532141E/pt unknown
- 2003-08-25 CA CA002497078A patent/CA2497078A1/en not_active Abandoned
- 2003-08-25 ES ES03794933T patent/ES2351119T3/es not_active Expired - Lifetime
- 2003-08-25 PL PL03375627A patent/PL375627A1/xx not_active Application Discontinuation
- 2003-08-25 JP JP2004535155A patent/JP2006506348A/ja active Pending
- 2003-08-25 DE DE50313185T patent/DE50313185D1/de not_active Expired - Lifetime
- 2003-08-25 MX MXPA05002298A patent/MXPA05002298A/es active IP Right Grant
- 2003-08-25 AT AT03794933T patent/ATE484503T1/de active
- 2003-08-25 SI SI200331896T patent/SI1532141T1/sl unknown
- 2003-08-28 PE PE2003000883A patent/PE20040983A1/es not_active Application Discontinuation
- 2003-08-29 AR ARP030103137A patent/AR041093A1/es unknown
-
2005
- 2005-02-28 US US11/066,981 patent/US7105538B2/en not_active Expired - Fee Related
-
2010
- 2010-11-17 CY CY20101101028T patent/CY1110913T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05002298A (es) | 2005-06-08 |
| JP2006506348A (ja) | 2006-02-23 |
| PT1532141E (pt) | 2010-11-02 |
| EP1532141B1 (de) | 2010-10-13 |
| SI1532141T1 (sl) | 2010-12-31 |
| DK1532141T3 (da) | 2010-11-22 |
| CN1678609A (zh) | 2005-10-05 |
| ES2351119T3 (es) | 2011-01-31 |
| US20050187260A1 (en) | 2005-08-25 |
| CA2497078A1 (en) | 2004-03-25 |
| US7105538B2 (en) | 2006-09-12 |
| PE20040983A1 (es) | 2005-01-12 |
| AR041093A1 (es) | 2005-05-04 |
| AU2003264097A1 (en) | 2004-04-30 |
| EP1532141A1 (de) | 2005-05-25 |
| PL375627A1 (en) | 2005-12-12 |
| RU2324694C2 (ru) | 2008-05-20 |
| RU2005109164A (ru) | 2006-01-20 |
| DE50313185D1 (de) | 2010-11-25 |
| DE10240818A1 (de) | 2004-05-13 |
| CN100390168C (zh) | 2008-05-28 |
| ATE484503T1 (de) | 2010-10-15 |
| WO2004024725A1 (de) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110558T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| CY1109142T1 (el) | Χαρακτηρισμος: σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
| CY1110318T1 (el) | Παραγωγα φαινοξυοξικου οξεος | |
| CY1108067T1 (el) | Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης | |
| CY1108085T1 (el) | Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπ-2-εν-1-ονης παρασκευη και χρησης αυτων | |
| CY1110258T1 (el) | Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης | |
| CY1113533T1 (el) | Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης | |
| CY1121877T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη | |
| CY1115199T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση | |
| CY1116272T1 (el) | Φαρμακευτικα σκευασματα που περιεχουν μεθυλναλτρεξονη | |
| CY1109568T1 (el) | Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων | |
| CY1108378T1 (el) | 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu | |
| CY1107975T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου με χημικη συγγενεια προς τον υποδοχεα orl1 | |
| CY1111903T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση | |
| CY1112115T1 (el) | Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου | |
| CY1113039T1 (el) | Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο | |
| CY1110812T1 (el) | Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων | |
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| ATE284388T1 (de) | Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden | |
| SE0200920D0 (sv) | Novel compounds | |
| ATE450501T1 (de) | Pentafluorsulfanyl-substituierte verbindung und deren verwendung zur herstellung von arzneimitteln |